Royalty Pharma may offer $6.6 billion bid for Elan

DUBLIN Mon Feb 25, 2013 10:14pm IST

File photo of Kelly Martin, CEO of Elan, speaking at the Reuters Health Summit in New York November 17, 2008. REUTERS/Brendan McDermid

File photo of Kelly Martin, CEO of Elan, speaking at the Reuters Health Summit in New York November 17, 2008.

Credit: Reuters/Brendan McDermid

Related Topics

Stocks

   
Border Security Force (BSF) soldiers ride their camels as they rehearse for the "Beating the Retreat" ceremony in New Delhi January 27, 2015. REUTERS/Ahmad Masood

"Beating The Retreat" Rehearsals

Rehearsals are on for "Beating the Retreat" ceremony which symbolises retreat after a day on the battlefield, and marks the official end of the Republic Day celebrations.  Slideshow 

DUBLIN (Reuters) - U.S. investment firm Royalty Pharma has made a $6.6 billion approach to Irish drugmaker Elan, targeting royalty rights for multiple sclerosis treatment Tysabri worth hundreds of millions of dollars annually.

Elan said earlier this month it was to sell its 50 percent interest in Tysabri for $3.25 billion plus future royalty payments to U.S. partner Biogen Idec, and then reinvent itself with a series of acquisitions.

Those royalty payments on future Tysabri sales, which rose 8 percent to $1.63 billion in 2012, will be 12 percent for the first year and 18 percent thereafter.

Royalty Pharma, which buys royalty streams of patented drugs and whose was indicative approach was worth $11 per Elan share, said on Monday that after the Biogen Idec deal, Elan would have two material assets - cash and the Tysabri royalty payments.

"The risks and lack of earnings visibility associated with Elan's acquisition and in-licensing strategy (are) substantial," it said. Elan shares were up 6.5 percent at $11.29 by 11.30 a.m. ET.

Royalty Pharma said Elan shareholders would be able to invest cash paid for their Elan Stock in other drug companies without paying a premium to gain control, as would likely be the case were Elan itself to buy a controlling stake in a company.

Elan, in which U.S. group Johnson & Johnson is an 18 percent shareholder, said Royalty Pharma's proposed bid was highly opportunistic because shareholders had not had the opportunity to assess the full benefit of the Tysabri sale.

Deutsche Bank analyst Richard Parkes said the small premium suggested by Royalty Pharma might deter Elan's shareholders.

"But it is not totally unreasonable. Investors are now faced with a straight question of whether you lock in the value at a small discount to asset value or you have faith that management can deliver on its planned strategy of acquiring assets."

Royalty Pharma said it had not received a formal response from Elan and had been unsuccessful in efforts to engage with the company since making contact on February 18.

It also said it was surprised by Elan's February 22 announcement that it planned to return $1 billion to shareholders buying back shares, because it did not address the proposed offer.

STRATEGY DISPUTE

Elan told Reuters last month it had spoken to several companies about potential deals.

Royalty Pharma said good assets in the industry were in short supply and Elan's senior management had little experience making acquisitions.

Royalty Pharma, whose portfolio includes rheumatoid arthritis drugs Humira and Remicade, last year paid $761 million for a stake in Biogen's MS treatment Tecfidera.

Royalty Pharma said it planned to finance any offer through a combination of available cash and debt, and was working with financial advisers led by J.P. Morgan and lenders led by BofA Merrill Lynch to put in place the necessary debt financing.

There was talk last year that Biogen might try to buy Elan outright, following the failure of the Irish company's Alzheimer's drug bapineuzumab, which it was working on with Johnson & Johnson and Pfizer.

(Editing by Dan Lalor and Mark Potter)

FILED UNDER:
Photo

After wave of QE, onus shifts to leaders to boost economy

DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.

Ebola Outbreak

Reuters Showcase

ONGC Share Sale

ONGC Share Sale

ONGC share sale scheduled for this fiscal - oil minister  Full Article 

The Apple logo is pictured inside the newly opened Omotesando Apple store at a shopping district in Tokyo June 26, 2014. REUTERS/Yuya Shino/Files

Record Earnings

Apple iPhone sales trample expectations as profit sets global record  Full Article 

'Umrika' At Sundance

'Umrika' At Sundance

From Oscars to Sundance, Sharma and Revolori discuss India's 'Umrika'  Full Article 

Australian Open

Australian Open

Smooth Wawrinka, ill Serena through to Melbourne semis   Full Article 

India's Male Tenor

India's Male Tenor

India's lone male tenor aims to sing opera in local key  Full Article 

Japan Hostages

Japan Hostages

Mother of Japanese captive begs PM to save son held by Islamic State  Full Article 

Tripoli Attack

Tripoli Attack

Frenchman, American among those killed in Tripoli hotel attack - Libyan official.  Full Article 

U.S. Blizzard

U.S. Blizzard

Blizzard hits Boston and New England, spares New York despite forecasts.  Full Article 

Spying Row

Spying Row

Spying program leaked by Snowden is tied to campaign in many countries.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage